Terms: = Ovarian cancer AND TPM3, ENSG00000143549, 7170
5 results:
1. Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW
Br J Cancer; 2021 Jul; 125(2):265-276. PubMed ID: 33981016
[TBL] [Abstract] [Full Text] [Related]
2. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of ovarian cancer: A Systematic Review and Meta-analysis.
Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
[TBL] [Abstract] [Full Text] [Related]
3. Whole solid tumour volume histogram analysis of the apparent diffusion coefficient for differentiating high-grade from low-grade serous ovarian carcinoma: correlation with Ki-67 proliferation status.
Li HM; Zhang R; Gu WY; Zhao SH; Lu N; Zhang GF; Peng WJ; Qiang JW
Clin Radiol; 2019 Dec; 74(12):918-925. PubMed ID: 31471063
[TBL] [Abstract] [Full Text] [Related]
4. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.
Tang HY; Beer LA; Tanyi JL; Zhang R; Liu Q; Speicher DW
J Proteomics; 2013 Aug; 89():165-78. PubMed ID: 23792823
[TBL] [Abstract] [Full Text] [Related]
5. Histotype-specific copy-number alterations in ovarian cancer.
Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
[TBL] [Abstract] [Full Text] [Related]
